



15 June 2015

Notice under Section 708A(5)(e) Corporations Act

On 15 June 2015, Optiscan Imaging Limited ("the Company") announced a pro-rata rights issue for up to 13,801,493 fully paid ordinary shares, the issue of 1,000,000 fully paid ordinary shares as a commitment fee for a debt placement and the issue of 3,000,000 options as an underwriting fee for the aforementioned rights issue.

Accordingly the Company gives notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (the "Corporations Act") that:

the abovementioned securities were issued without disclosure to investors under Part 6D.2 of the Corporations Act;

1. as at the date of this notice the Company has complied with:
 - (a) the provisions of Chapter 2M Corporations Act as they apply to the Company; and
 - (b) section 674 Corporations Act; and
2. as at the date of this notice there is no "excluded information" (as defined in subsection 708A(7) of the Corporations Act) which is required to be disclosed by the Company.

Yours faithfully

Optiscan Imaging Limited

A handwritten signature in blue ink, appearing to read "B R Andrew".

B R Andrew
Company Secretary

About Optiscan

Optiscan is a global leader in microscopic imaging technologies for medical markets. Optiscan's unique and patented technologies enable high-powered microscopes to be miniaturised and used inside the body. The technology enables microscopic imaging of up to 1000 times magnification to be achieved. Doctors can use the technology to instantly see cellular level details of tissue without the requirement to surgically remove tissue (biopsy).

Further information:

Gus Holt, Chairman
Tel (613) 9538 3347
GusH@optiscan.com

Bruce Andrew, CFO
Tel (613) 9538 3398
brucea@optiscan.com